Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company that specializes in discovering and developing therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. Its lead product candidate, inarigivir soproxil, is aimed at treating chronic hepatitis B virus. The company also has other SMNH product candidates in its pipeline, including an immunotherapeutic agent to potentially treat certain cancers. Spring Bank Pharmaceuticals has a strategic partnership with Gilead Sciences to conduct a Phase II trial on the combination of inarigivir and tenofovir alafenamide for HBV patients. The company was founded in 2002 and is headquartered in Massachusetts.